Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 19/20 | 0.68 |
| ▸ | NQO2 | P16083 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1296470 | 0.99 | MET (0.68) | METNQO2 | |
| Hydrochloric Acid SCHEMBL1295618 | 0.99 | MET (0.68) | METNQO2 | |
| SCHEMBL2514985 | 0.93 | MET (0.66) | METNQO2 | |
| Hydrochloric Acid SCHEMBL17823305 | 0.91 | MET (0.65) | METNQO2 | |
| SCHEMBL2512836 | 0.90 | MET (0.73) | METNQO2 | |
| SCHEMBL18204293 | 0.89 | MET (0.54) | METNQO2 | |
| SCHEMBL3092215 | 0.88 | MET (0.71) | METNQO2 | |
| SCHEMBL2462450 | 0.87 | MET (0.82) | METNQO2 | |
| SCHEMBL30523589 | 0.87 | MET (0.82) | METNQO2 | |
| Hydrochloric Acid SCHEMBL28511707 | 0.85 | MET (0.49) | METNQO2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 140 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4599885-A2 | COMPOUNDS FOR THE TREATMENT OF GLIOBLASTOMA | Merck Patent GmbH (DE) | 2025-08-13 | — | — | EP | claimed |
| US-20240277711-A1 | COMPOUNDS FOR THE TREATMENT OF GLIOBLASTOMA | MERCK PATENT GMBH (DE) | 2024-08-22 | — | — | US | claimed |
| CN-114025761-B | Pharmaceutical preparation | 默克专利股份公司 | 2024-07-16 | — | — | CN | claimed |
| CN-117794541-A | Compounds for the treatment of glioblastoma | 默克专利股份公司 | 2024-03-29 | — | — | CN | claimed |
| EP-4260910-A2 | PHARMACEUTICAL PREPARATION | Merck Patent GmbH (DE) | 2023-10-18 | — | — | EP | claimed |
| EP-3996688-B1 | PHARMACEUTICAL PREPARATION | MERCK PATENT GMBH (DE) | 2023-09-06 | — | — | EP | claimed |
| EP-3229796-B1 | COMBINATION OF A 6-OXO-1,6-DIHYDRO-PYRIDAZINE DERIVATIVE HAVING ANTI-CANCER ACTIVITY WITH A QUINAZOLINE DERIVATIVE | MERCK PATENT GMBH (DE) | 2023-03-01 | — | — | EP | claimed |
| US-20220288068-A1 | PHARMACEUTICAL PREPARATION | MERCK PATENT GMBH (DE) | 2022-09-15 | — | — | US | claimed |
| EP-3996688-A1 | PHARMACEUTICAL PREPARATION | Merck Patent GmbH (DE) | 2022-05-18 | — | — | EP | claimed |
| CN-114025761-A | Pharmaceutical preparation | 默克专利股份公司 | 2022-02-08 | — | — | CN | claimed |
| EP-2373640-B1 | NOVEL POLYMORPHIC FORMS OF 3-(1-{3-[5-(1-METHYL-PIPERIDIN-4YLMETHOXY)-PYRIMIDIN-2-YL]-BENZYL}-6-OXO-1,6-DIHYDRO-PYRIDAZIN-3-YL)-BENZONITRILE HYDROCHLORIDE SALT AND PROCESSES OF MANUFACTURING THEREOF | MERCK PATENT GMBH (DE) | 2014-07-30 | — | — | EP | claimed |
| US-20140200221-A1 | NOVEL POLYMORPHIC FORMS OF 3-(1--6-OXO-1,6-DIHYDRO-PYRIDAZIN-3-YL)-BENZONITRILE HYDROCHLORIDE SALT AND PROCESSES OF MANUFACTURING THEREOF | MERCK PATENT GMBH (DE) | 2014-07-17 | — | — | US | claimed |
| WO-2014067610-A1 | A 6-OXO-1,6-DIHYDRO-PYRIDAZINE DERIVATIVE FOR THE USE FOR THE TREATMENT OF HEPATOCELLULAR CARCINOMA (HCC) | MERCK PATENT GMBH (DE) | 2014-05-08 | — | — | WO | claimed |
| US-8710058-B2 | Polymorphic forms of 3-(1-{3-[5-(1-methyl-piperidin-4-ylmethoxy)-pyrimidin-2-yl]-benzyl}-6-oxo-1,6-dihydro-pyridazin-3-yl)-benzonitrile hydrochloride salt and processes of manufacturing thereof | MERCK PATENT GMBH (DE) | 2014-04-29 | — | — | US | claimed |
| US-8658643-B2 | Pyrimidinyl pyridazinone derivatives | MERCK PATENT GMBH (DE) | 2014-02-25 | — | — | US | claimed |
| US-8580781-B2 | Pyridazinone derivatives | MERCK PATENT GMBH (DE) | 2013-11-12 | — | — | US | claimed |
| WO-2013139423-A1 | COMBINATION OF A 6-OXO-1,6-DIHYDRO-PYRIDAZINE DERIVATIVE HAVING ANTI-CANCER ACTIVITY WITH OTHER ANTI-TUMOR COMPOUNDS | MERCK PATENT GMBH (DE) | 2013-09-26 | — | — | WO | claimed |
| US-20110269767-A1 | Novel Polymorphic Forms of 3-(1--6-oxo-1,6-dihydro-pyridazin-3-yl)-benzonitrile Hydrochloride Salt and Processes of Manufacturing Thereof | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2011-11-03 | — | — | US | claimed |
| EP-2373640-A1 | NOVEL POLYMORPHIC FORMS OF 3-(1-{3-[5-(1-METHYL-PIPERIDIN-4YLMETHOXY)-PYRIMIDIN-2-YL]-BENZYL}-6-OXO-1,6-DIHYDRO-PYRIDAZIN-3-YL)-BENZONITRILE HYDROCHLORIDE SALT AND PROCESSES OF MANUFACTURING THEREOF | Merck Patent GmbH (DE) | 2011-10-12 | — | — | EP | claimed |
| WO-2010078897-A1 | NOVEL POLYMORPHIC FORMS OF 3-(1-{3-[5-(1-METHYL-PIPERIDIN-4YLMETHOXY)-PYRIMIDIN-2-YL]-BENZYL}-6-OXO-1,6-DIHYDRO-PYRIDAZIN-3-YL)-BENZONITRILE HYDROCHLORIDE SALT AND PROCESSES OF MANUFACTURING THEREOF | MERCK PATENT GMBH (DE) | 2010-07-15 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140200221-A1 | NOVEL POLYMORPHIC FORMS OF 3-(1--6-OXO-1,6-DIHYDRO-PYRIDAZIN-3-YL)-BENZONITRILE HYDROCHLORIDE SALT AND PROCESSES OF MANUFACTURING THEREOF | BRCA1, MAPK4, MAPK1 | MET 1452/4885NQO2 2900/4885 |
| US-20220288068-A1 | PHARMACEUTICAL PREPARATION | CYP3A4, CYP2D6, CYP3A7 | MET 4006/4885NQO2 1152/4885 |
| US-20110269767-A1 | Novel Polymorphic Forms of 3-(1--6-oxo-1,6-dihydro-pyridazin-3-yl)-benzonitrile Hydrochloride Salt and Processes of Manufacturing Thereof | BRCA1, MAPK4, MAPK1 | MET 1452/4885NQO2 2900/4885 |
| US-20240277711-A1 | COMPOUNDS FOR THE TREATMENT OF GLIOBLASTOMA | MET, MGMT, EGFR | MET 1/4885NQO2 3689/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.